Peripheral Arterial Disease Pipeline Analysis and Clinical Trial Report 2023: Featuring 18+ Key Companies by DelveInsight

Posted on
by

Peripheral Arterial Disease Pipeline Analysis and Clinical Trial Report 2023: Featuring 18+ Key Companies by DelveInsight
Peripheral Arterial Disease Pipeline

DelveInsight’s ‘Peripheral Arterial Disease Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and Peripheral Arterial Disease pipeline therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Peripheral Arterial Disease pipeline domain.

 

 

For further information on the Peripheral Arterial Disease Pipeline report offerings, download free sample @ Peripheral Arterial Disease Pipeline Insight

 

Key takeaways from the Peripheral Arterial Disease Pipeline Report

  • Over 18+ Peripheral Arterial Disease pipeline therapies are in various stages of development, and their anticipated acceptance in the Peripheral Arterial Disease market would significantly increase market revenue.
  • The leading Peripheral Arterial Disease Companies developing novel drug candidates to improve the Peripheral Arterial Disease treatment landscape include NovoNordisk, Takeda, Mercator MedSystems, Inc., Beijing Northland Biotech. Co., Ltd., Ixaka Ltd, Humacyte, Inc., CardioVascular BioTherapeutics, Proteon Therapeutics, ReNeuron Limited, Alucent Biomedical, Athersys, ARCA biopharma, Ambulero, Venturis Therapeutics, and others.
  • Promising Peripheral Arterial Disease Pipeline therapies in various stage of development include Simvastatin, Losartan, Pioglitazone, Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban, HAV implantation, CorPath 200 System, BioMimics 3D Vascular Stent System, Cotavance Drug-Eluting Balloon, Medications and Standard walking exercises, and others.
  • The Peripheral Arterial Disease companies and academics are working to assess challenges and seek opportunities that could influence Peripheral Arterial Disease R&D. The Peripheral Arterial Disease therapies under development are focused on novel approaches to treat/improve Peripheral Arterial Disease.

 

Request a sample and discover the recent breakthroughs happening in Peripheral Arterial Disease pipeline landscape @ Peripheral Arterial Disease Pipeline Outlook Report

 

Peripheral Arterial Disease Overview

Peripheral artery disease (PAD) refers to diseases of the blood vessels located outside the heart and brain. PAD is a chronic disease in which plaque builds up in the arteries of the legs. It is more common in people who are 65 or older, but can occur at nearly any age. Smoking; high blood pressure; high cholesterol or triglycerides; diabetes; kidney failure; and obesity increase risk for PAD. While many people with peripheral artery disease have mild or no symptoms, some people have leg pain when walking.

 

Emerging Peripheral Arterial Disease Drugs

  • Semaglutide: Novo Nordisk

Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently in Phase III stage of development for the treatment of patients with Type 2Diabetes Mellitus, and Peripheral Arterial Disease.

  •  VM202: Helixmith

Engensis (VM202) is an investigational gene therapy being developed by Helixmith, formerly known as ViroMed. Helixmith’s non-viral plasmid DNA product, Engensis, is designed to express recombinant HGF protein in nerve and Schwann cells to promote nerve system regeneration and induce the formation of microvascular blood vessels. Engensis (VM202) has the potential to promote blood vessel formation in the ischemic area by HGF-based angiogenesis. In addition, the HGF-based angiogenesis may also contribute to cardiac muscle function improvement through the suppression of apoptosis and cardiac fibrosis.

 

Find out more about the diagnosis and treatment of patients with Peripheral Arterial Disease @ Peripheral Arterial Disease Ongoing Clinical Trials Analysis

 

Peripheral Arterial Disease Key Companies and Pipeline Therapies

  • NovoNordisk: Simvastatin
  • Takeda: Losartan
  • Mercator MedSystems, Inc.: Pioglitazone
  • Beijing Northland Biotech. Co., Ltd.: Rivaroxaban (Xarelto, BAY59-7939)
  • Ixaka Ltd: Rivaroxaban:
  • Humacyte, Inc.: HAV implantation
  • CardioVascular BioTherapeutics: CorPath 200 System
  • Proteon Therapeutics: BioMimics 3D Vascular Stent System
  • ReNeuron Limited: Cotavance Drug-Eluting Balloon
  • Alucent Biomedical: Medications and Standard walking exercises

 

Peripheral Arterial Disease Pipeline Therapeutics Assessment

Phases

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Route of Administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type

Molecule Type

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Scope of the Peripheral Arterial Disease Pipeline Report

  • Coverage- Global
  • Peripheral Arterial Disease Companies- NovoNordisk (NYSE: NVO), Takeda (NYSE: TAK), Mercator MedSystems, Inc., Beijing Northland Biotech Co Ltd., Ixaka Ltd, Humacyte Inc (NYSE: HUMA), CardioVascular BioTherapeutics (NYSE: CVBT),  Proteon Therapeutics, ReNeuron Limited (NYSE: RNUGF), Alucent Biomedical, Athersys (NYSE: ATHX), ARCA biopharma (NYSE: ABIO), Ambulero, Venturis Therapeutics, and others.
  • Peripheral Arterial Disease Pipeline Therapies- Simvastatin, Losartan, Pioglitazone, Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban, HAV implantation, CorPath 200 System, BioMimics 3D Vascular Stent System, Cotavance Drug-Eluting Balloon, Medications and Standard walking exercises, and others
  • Peripheral Arterial Disease Therapeutics Assessment: Phases, Route of Administration, Molecule Type

 

Dive deep into rich insights for Peripheral Arterial Disease Emerging Therapies and assessment; visit @ Peripheral Arterial Disease Treatment Landscape

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Peripheral Arterial Disease: Overview
  4. Peripheral Arterial Disease Pipeline Therapeutics
  5. Peripheral Arterial Disease Therapeutic Assessment
  6. Peripheral Arterial Disease – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Peripheral Arterial Disease Collaboration Deals
  9. Late Stage Products (Phase III) 
  10. Semaglutide: Novo Nordisk
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II) 
  13. AMG0001: AnGes USA, Inc.
  14. Drug profiles in the detailed report…..
  15. Early stage products (Phase I/II)
  16. Drug Name: Company Name
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Peripheral Arterial Disease Key Companies
  20. Peripheral Arterial Disease Key Products
  21. Peripheral Arterial Disease Unmet Needs
  22. Peripheral Arterial Disease Market Drivers and Barriers
  23. Peripheral Arterial Disease Future Perspectives and Conclusion
  24. Peripheral Arterial Disease Analyst Views
  25. Peripheral Arterial Disease Key Companies
  26. Appendix

 

For further information on the Peripheral Arterial Disease Pipeline therapeutics, reach out @ Peripheral Arterial Disease Companies & Therapies

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services